13241-32-2
Chemical Structure
Neoeriocitrin
- No. CAS: 13241-32-2
- Formula:C27H32O15
- Molecular Weight:596.53
IUPAC Name: (S)-7-(((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-2-(3,4-dihydroxyphenyl)-5-hydroxychroman-4-one
InChIKey: OBKKEZLIABHSGY-DOYQYKRZSA-N
SMILES: O=C1C2=C(O)C=C(O[C@H]3[C@@H]([C@H]([C@H](O)[C@@H](CO)O3)O)O[C@@]4([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O4)O)O)C=C2O[C@H](C5=CC(O)=C(O)C=C5)C1
Biological Activity: Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease[1][2][3][4].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Neoeriocitrin | 99.97% | Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Neoeriocitrin (Standard) | ≥98% | Neoeriocitrin (Standard) is the analytical standard of Neoeriocitrin (HY-N4119). This product is intended for research and analytical applications. Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.92
HY-N0101RNeohesperidin (Standard) -
Similarity Score 0.89
HY-N0153RNaringin (Standard) -
Similarity Score 0.88
HY-N0636REriocitrin (Standard) -
Similarity Score 0.86
HY-N2258Poncirin -
Similarity Score 0.82
HY-15337Hesperidin -
Similarity Score 0.81
HY-N13190(2R)-Eriodictyol-7-O-β-D-glucopyranoside -
Similarity Score 0.81
HY-N3847Eriodictyol-7-O-glucoside -
Similarity Score 0.80
HY-N88347-Neohesperidosides -
Similarity Score 0.79
HY-N16682Pyrroside A -
Explore the MedChemAI to find more analogs
References
- [1]. Li L, et al. Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine. 2011;18(11):985-989. [Content Brief]
- [2]. Wu Y, et al. Neoeriocitrin Targeting Beclin1 Deubiquitination and Autophagy in Osteogenic Differentiation of Human Dental Pulp Stem Cells. Adv Sci (Weinh). 2025;12(43):e04378. [Content Brief]
- [3]. NISHIURA M, et al. Flavonoids in Citrus and related genera Part II. Isolation and identification of isonaringin and neoeriocitrin from Citrus[J]. Agricultural and Biological Chemistry, 1971, 35(11): 1683-1690.
- [4]. van der Meer JW, et al. Abstract!. Neth J Med. 2002;60(11):418. [Content Brief]
